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“It is not a disease on which to build a medical reputation”  
E. Wilson 
1. Introduction 
Psoriasis is probably as old as mankind. Today, it is a well defined skin disease, in which 
genetic, environmental and immunologic factors participate in etiopathogenesis. However, 
despite its frequency, chronicity and visibility, it is quite hard to find a description of 
psoriasis in the works of the ancient physicians.  
Dermatology developed slowly, first with appearance of the protodermatologists at the end 
of the 18th century, and continued with the arrival of the first dermatologists. From those 
times psoriasis became a distinct entity.  
However, until the last century, the descriptions of disease considered «morbi in 
pulchredine», were rather vague, the denomination not standardized and the translation 
from one language to others discrepant. Different authors called the disease with various 
names, while diverse diseases had the same names. The confusion in terminology and 
description of psoriasis lasted for centuries. 
2. Psoriasis through history: Description and definition  
2.1 Psoriasis in the old age 
The medicine developed in Mesopotamia, peopled by Sumers, Assirs, and Babylons. The 
oldest written witness regarding their medicine is clay tablets 3000-5000 year old (Radbill, 
1975). Skin diseases have been known to Mesopotamian physicians, called asu, but was 
cured usually by seers and priests. Definitely there is not notice of psoriasis.  
According to Herodotus in the pharaonic Egypt there were physicians for every organ. 
Numerous medicaments were used, along with magical ceremonies and enchantments 
(Herodotus, 1989). Hovewer, nothing relate to psoriasis in their medical papyruses. In the 
largest writing, the Ebers papyrus written about the 15th century BC, found in 1873 in 
Luxor, numerous skin diseases were described (paragraph 90-95 and 104-118). The term šuf. 
t for scale was find, but it was impossible to recognize psoriasis (Ebbel, 1937). 
Data about medicine among ancient Hebrews were scarce, mostly preventive in nature, and 
can be found only in their religious books the Old Testament and the Talmud. In the 
Leviticus, a short description of a cutaneous disease called zaraath (translated in Greek as 
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lepra) was found, which some believed to be leprosy, psoriasis, vitiligo, fungal diseases, or 
even some other skin condition (Goldman et al., 1966).  
The Ayurvedic, religious medicine, developed in India during antiquity. It was based on 
magic-religious rites, with using of certain plants. Among the medical books from that 
period the great importance had the Charaka Samitha. In this book and in the Bower 
manuscript, the disease named Khusta was described briefly. The disease was probably 
leprosy, although Paul Richter supposed it was psoriasis (Menon & Haberman, 1969; 
Richter, 1928). 
In the golden age of Greek science, the father of western medicine - Hippocrates (ca. 460- 377 
BC), separated diseases from divine influences and religious procedures. He used the word 
psora that meant itch for itchy lesions on the eyelids and genitals. This condition was not 
psoriasis undoubtedly, though he used tars and climate to treat that disease (Hippocrate, 
1839). He also grouped various skin conditions under the term of lopoi, that in Greek mean 
scale and introduced the word alphos and leukos for some skin diseases with maculae but 
doubtless not for psoriasis (G. Sticker, 1931). 
The first description of psoriasis appear during the Roman Empire in the 1st century AD in 
the books of A. Cornelius Celsus » De re medica libri octo». The disease was described as 
impetigo that can appear on the skin of the extremities and nails (the second, the 4th or third 
type according to different authors). The disease was treated with medicaments containing 
pitch and sulphur. Interestingly, Celsus did not use the words psoriasis, psora, lepra 
(Bechet, 1936).   
The word psora had been mentioned in the books «Naturalis historia» of the other Roman 
encyclopedist Pliny, but he did not describe better the disease, for which he recommended 
the root of cucumber. It is possible that the term alphos also described psoriasis (Celsus, 
1989).  
Galen (131-201 AD) of Pergamon, physician of some Roman imperators, was the first who 
used the term psoriasis, but only for an itchy, scaly eruption of the eyelids and scrotum, that 
was probably seborrheic dermatitis (Galenus, 1830; Plinius, 1969). 
In the manuscripts of the greatest physicians of antiquity we found little about psoriasis, 
probably because they gave little importance to the skin, believing the organ merely a web 
to hold together the other parts of the body. Recently Karl Holubar wrote minutely about 
the semantic aspects of the word psoriasis, and stated that no clear clinical description of 
psoriasis can be found in the works of the ancient writers (Holubar, 1990). 
In the pre-Columbian period in America the Maya, the Aztecs, the Incas, and the Nahuas 
had a kind of medicine in which magic and religious elements were interwoven, but also 
treated skin diseases with plants. A disease, probably psoriasis, they treated topically and 
internally with herbs and resins (Obermeyer, 1974). 
2.2 Psoriasis in the middle age 
After the extinction of the Roman Empire by the Goths take place the darkness of the 
Middle Age, a period of stagnation  which negatively affected the development of science 
(Porter, 1999).  The literate men were confined to monastic cloisters and medicine was full of 
superstition, ignorance and mysticism and gave little attention to skin diseases. Writers 
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according to Hebra spent their time in frivolous commentaries of the ancient  classic writers, 
physicians or no, while the cause of the diseases remained unknown (Bechet, 1936). The 
majority of the people was cured by quacks and barbers often illiterate.  
The Arabian physicians perhaps first distinguished psoriasis from other skin diseases 
already in the VIII century A.D., and it seem they used a kind of psychotherapy in treatment 
(Shafii & Shafii, 1979). 
In Western the first medical School was founded in Salerno, where Constantine the African 
translated old medical manuscripts from Greek and Arabic to Latin. By the 13th century 
most manuscripts had been translated into Latin that became the dominant language of the 
educated people. 
2.3 Psoriasis in the renaissance   
The Renaissance was a cultural movement that spanned roughly the 14th to the 17th 
century, beginning in Florence in the Late Middle Ages and later spreading to the rest of 
Europe. During this time some authors mentioned the diseases psora and lepra in their 
books. Among these was Johannes Manardi (1462-1536) from Ferrara, who mentioned the 
disease “psora” in his ”Epistolae medicinales”, but wrote nothing more about 
(Manardi,1542).  
The most important work on skin disease was written by Hieronymus Mercurialis (1530-
1606), professor of medicine at the universities of Padua, and Bologna. The book was 
entitled »De morbis cutaneis et omnibus corporis humani excrementis» and based on his 
lectures transcribed by his student Acardius. For this book Garrison said «the first 
systematic text book on diseases of the skin”. Mercurialis divided the skin diseases, similarly 
to Galen “a capite ad pedes” in those of the scalp and then of the entire body, both 
subdividing in change of the color, change in structure and bulks. He described psoriasis 
under the name of “lepra grecorum” and for other condition used the term “psora” 
(Mercurialis, 1572).   
In 1700, B. Ramazzini (1633-1714) published his original work ”De morbis artificum 
diatriba” in which the diseases caused by the work in certain professions was described, 
among them also skin conditions. Ramazzini pointed out a lot of new causes of diseases 
different from the Hippocrates’s theory of a dyscrasia of humors (Ramazzini, 1700). 
2.4 Psoriasis in 18th century 
During the 18th century a few surgeons and physicians tried to devote oneself to the study 
of the skin and its diseases. Among them was Daniel Turner (1667-1740), who firstly started 
to work as a surgeon, then obtained in America at Yale a honorary degree of doctor 
medicine. In 1714 he published the book entitled «De morbis cutaneis a treatment of 
diseases incident to the skin», that went through a few editions and was soon translated in 
other languages (Turner, 1726). He gave not an accurate description of psoriasis that he 
called “leprosy of the Greek”, while “leprosy of the Arabian” was our leprosy. He was 
aware that the local application of ointments and drugs transfer them internally.  
In the second part of the 18th century the great Swedish naturalist and physician Carl 
Linnaeus (1707-1787) introduced the binomial terminology and first classified the plants in a 
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comprehensible manner. In 1735 he published this in his book »Systema naturae» and later 
even proposed to classify the human diseases in his «Genera morborum» (Linnaeus, 1763). The 
same topic, in the same year, one can find in Francois Boissier de Sauvages who in his work 
»Nosologia methodica” classified diseases in ten classes with about 2400 species (Grmek, 
1996). These types of classifications were soon used in the classification of skin diseases. 
In 1777 Charles Anne Lorry (1726-1783), who became the physician of Louis XVI and can be 
considered the first French dermatologist, published in Paris his «Tractatus de morbis 
cutaneis». The book contained more than 700 pages, in which one can find the first attempt 
of an etiologic classification of skin diseases as well the interaction between internal organs, 
especially the gastrointestinal, nerve system and the “skin organ” (organum constitutit). 
Perhaps he was the first who described the Auspitz sign (Lorry, 1777). 
Joseph Jacob von Plenck (1738-1807) a Hungarian excellent surgeon and obstetrician in 
Vienna and expert in botany compiling a list of about 800 medicinal plants, in 1776 
published the little book entitled «Doctrina de morbis cutaneis». In his book the diseases 
was classified on morphological basis i.e. the elementary lesions of 120 skin diseases in 14 
classes, even the entities were often unidentifiable (Plenck, 1776). He gave only marginally 
attention to psoriasis (seated in the class of squames) and its therapy, and used the old term 
impetigo for it (from Latin impetus – to attack).  
For long time the surgeon treated skin diseases and therefore D. Turner, C. Lorry, and J. 
Plenck can be considered the protodermatologist (Holubar & Ferenčić, 2002). Their effort 
opened the way to the first dermatologist like R.Willan and JL. Alibert. 
Two decades after Plenck, the English physician Robert Willan (1757-1812), working at the 
London Public Dispensary published the Book «On cutaneous disease»  in which he 
developed a simpler, better and usable classification of the skin diseases on the basis  of 
eight elementary lesions (Willan, 1798). He used the term psoriasis for the papulosquamous 
disease, in the order squamae, together with lepra, pityriasis and ichthyosis and partly 
differentiated psoriasis from leprosy (psora leprosa and lepra grecorum). He described 
different forms of psoriasis: guttata, diffusa, gyrata, palmaria, unguium, inveterata. He also 
noticed that the disease begin on the knees and elbows, attack the scalp and also the finger 
and toe-nails. During his life he published the skin diseases of the first four orders (Willan, 
1809). After his premature death, his work was continued and completed by his disciple and 
successor Thomas Bateman (1778-1821), who also published some books on the subject 
paying attention on the treatment.  
At the beginning of the XIX century the great French physician Jean Louis Alibert (1768-
1837) worked and taught at the Hospital of St. Louis in Paris, dedicated to skin diseases. He 
opposed to Willan classification and also attempt to make order and systematize the skin 
diseases. He followed the ideas to classify diseases in agreement with another botanist B. de 
Jussieu based on the analogy and divided the skin diseases in 12 classes or groups. He also 
later (1829) proposed an « arbre des dermatoses» (in English-tree of skin diseases), a rather 
naive scheme, which made only a greater confusion. Psoriasis classified in the group of 
dartrous dermatoses together with leprosy (Alibert, 1832). 
In this century hospitals or dispensaries were opened only for treatment of skin or venereal 
diseases giving to the physicians the opportunity to study more cases of skin diseases and 
psoriasis as well. 
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It was Ferdinand von Hebra (1806-1880) who in 1841, working in Vienna at the Allgemeines 
Krankenhaus definitely divided psoriasis from leprosy (improving the terminology and 
classification of R. Willan). He was a popular teacher and  became the first professor of 
dermatology of German languages, and more importantly he classified the skin diseases in 
12 groups not only on the basis of gross anatomy, but after Karl Rokitansky (1804-1878) used 
also the microscopic criteria for their classification (Hebra, 1856), introducing general 
pathology to describe skin diseases. Regard psoriasis treatment he believed in pilulae 
asiaticae (arsenic) (Bechet, 1936). His successor Moritz Kaposi also continued on this way. 
2.5 Psoriasis in 19th century 
During the 19th century the dermatologists continued to dispute about the classification of 
skin diseases. Dermatology and also psoriasis grew and develop with the introduction of 
pathohistological classifications (F. Hebra, Auspitz). Regard psoriasis it is to underline that 
Alibert noted in 1822 the association of the disease with joint deformities (Alibert, 1818), for 
which Besnier coined the name arthritis psoriatica. The association was later detailed by 
Charles BOURDILLON (Bourdillon,1888), while Erasmus Wilson described the association 
of psoriasis with gout and rheumatic diseases.  
The description of the varieties of psoriasis followed: psoriasis pustulosa generalisata in 
1910 by Leo von Zumbusch (1884-1940) (von Zumbusch,1910), and later the of psoriasis 
palmo-plantaris by Barber-Königsbeck. 
Some authors described signs that helped the diagnosis of this disease. Heinrich Köbner 
(1838-1904), professor of dermatology in Breslau, described the isomorphous effect of 
irritation or Köbner phenomenon in 1872, i.e.  appearence of a psoriatic lesion at the site of a 
physical or other injury (Köbner,1877). Later this phenomenon was used experimentally to 
study the early changes that appear in the disease.  
 Heinrich Auspitz (1835-1886), a Hebra pupil, described the appearance of papillary 
bleeding after the removal of the scales from a psoriatic lesion (Auspitz sign or bloody dew 
phenomenon), even this sign had been before noted by D.Turner, R.Willan and F.Hebra. 
Auspitz was interested in dermatopathology, and introduced a few pathohistological terms 
such parakeratosis and acanthoma typical for psoriasis (Pusey, 1933). In 1879 Duncan and 
Bulckley described the “pellicole decolable”. Hard debates followed about the possibility of 
psoriatic manifestation on mucous membranes particularly on the oral cavity. 
At the end of the 19th century psoriatic micro morphology was described by Hebra, Unna, 
and William Munro who described the microabscess (micropustule), i.e. the accumulation of 
neutrophils in the stratum corneum. 
2.6 Psoriasis in 20th century 
During the first part of the 20th century the Woronoff ring was described around the 
psoriatic plaque (1926) especially after treatment with antrarobin (Woronoff , 1926; Kogoj , 
1927) 
The spongiform pustule in pustular psoriasis was described 1927. by Franjo Kogoj (1894-
1981) who working in Zagreb and later better defined by Mladen Rupec through  a 
ultramicroscopic study (Kogoj,1927; Rupec, 1970).  
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In the second part of the 20th century it was demonstrated that the psoriatic epidermis 
contains 25 times more mitoses per unit than the epidermis from healthy persons. van Scott 
and Ekel demonstrated that the keratinocytes of psoriatic patients have a significant 
shortening of their cell cycle from about 311 h in normal person to 36 h; (van Scott, 1963) and 
the turnover time of the epidermis is markedly shortened, from 27 days to 4 days ( 
Weinstein, 1968).  
In 20th century many authors studied the genetic alteration and today there is undisputed 
evidence that the disease is multifactorial i.e. caused by multiple genes. Many of these “ 
susceptible “ genes are mapped on different chromosomes (PSOR1-PSOR 10). The disease is 
triggered also by different environmental factors (Sanchez, 2007; Bowcock & Barker, 2003).  
The association with the HLA molecules was described especially for type 1 of psoriasis, 
that is frequently inherited, has a more severe course and develops early, while in type 2 the 
disease develop later and is rarely inherited (Henseler & Christopher, 1985). 
Last decades numerous immunological researches accumulate evidence of presence of 
alteration of the innate and adaptive immune response in psoriatic patients. Investigations 
evidentiated an accumulation of activated lymphocytes, mostly CD4 in the dermis and CD8 
in the epidermis. This imply a primary disregulation in of the immune system and 
permitted a better understanding and new insight in the pathogenesis as well new 
possibilities in the management of psoriasis (Krueger, 2002). Psychological stress also can 
influence the course of the disease. 
3. The treatment of psoriasis through history 
D. Turner describe very realistically in his book cases of psoriasis treated with inunctions of 
a ointment containing ammoniated mercury (Hydrargyri amidochlorati) or with a broth of 
boiled vipers (Turner, 1726). Although very interesting, such details of the treatment are 
beyond the scope of our article. As the diagnosis of psoriasis before the 19th century was 
rather debatable, and the treatment usually problematic and ingenuous, we will expose the 
treatment of psoriasis from the beginning of the XIX century. The treatment of course was 
topical and/or internal, but for a long period of time the physicians gave more attention to 
the internal, believing that the external application of drugs on the skin can drive inward the 
lesions and so cause « metastases» to the internal organs. It was Hebra who asserted this is 
only speculation. 
3.1 The treatment of psoriasis in 19
th
 century 
One of the first used internally medicaments for psoriasis treatment was arsenic. In 1806 
Thomas Girdlestone was the first who used potassium arsenite as solutio Fowleri, following 
a moderate use, usually 6 drops 3 times a day (Girdlestone, 1806). This solution was 
introduced into medicine in 1780 by the English physician and pharmacist Fowler (Fowler, 
1786). The drug was easily absorbed and then deposited in various organs, especially in the 
skin and hair, actihg through inhibiting some enzymes. Years after, F. Hebra, M.Kaposi and 
E. Wilson also recommended solutio Fowleri (before a meal in water or a bland tea) and 
pilulae asiaticae (consisting of arsenic, black pepper, acacia and water) in the treatment of 
psoriasis (Bechet, 1936). It seems that arsenic compounds improved mostly psoriasis guttata, 
sometimes other forms of the disease.  
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In 1869 Lipp introduced the subcutaneous injections of arsenous acid (Piffard, 1881).  
The protracted use of arsenic in a chronic disease like psoriasis with time led to its 
accumulation and toxicity. On the skin, liver, and other organs pigmentations, keratoses and 
malignant tumors appeared. In spite of this horrible adverse reactions arsenic remained in 
use to the middle of the XX century and the introduction of corticosteroids in the therapy of 
psoriasis (Gruber et al., 2004). 
Mercury was used for centuries in the treatment of syphilis and skin diseases. Mercury 
ointments was used also by Bateman and by other physicians  during the XIX century. 
According to Henry Pfiffard (1842-1910) the internal use of calomel was also extolled by 
Biett, Rayer and other physicians (Piffard, 1881) Brault in 1895 used organic mercury 
compound injections in the treatment of arthritis psoriatica (Brault, 1895). Still in 1972 W. 
Jadassohn and F. Kogoj recommended a mercury ointment for psoriasis capillitii (Jadassohn 
& Kogoj, 1972). 
Many disease as well as psoriasis were considered infectious diseases and an antibacterial 
treatment introduced (iodine, phenol, acetic acid).  Among other drugs used internally for 
psoriasis treatmen were diuretics (petroselinum apium, foliae uvae ursi, digitalis, tinctura 
cantharides), with little benefit.  
The local or internal (intramuscular) use of sulphur and salicylic acid in treatment of skin 
disease in general is very old. Hebra and Kaposi used sulphur and salicylic acid in various 
ointments, obtaining the removal of the scales (Hebra, 1845).  
For centuries in India Chrysarobin was used in the treatment of dermatomycoses and 
perhaps psoriasis i.e. long before the English physician Balmanno Squire in 1876 wrote 
about its use for psoriasis (Squire, 1878). The drug was present in the Goa (or Bahia) 
powder, obtained from the center of the trunk of the tree Andira Araroba (Vataireopis 
araroba), which grows in some parts of Brasil (Swanbeck, 1992). Chrysarobin is an antranone 
that easily oxidizes and its concentration in the powder was very variable. This drug was 
used in the form of 1-5% ointment and when applied on skin it cause itching and colored the 
skin and linen. These effects prevented a larger use of this drug at home. The drug was 
effective, but expensive and toxic.  
3.2 The treatment of psoriasis in the 20
th
 century 
Around the change of the century the development of chemistry and technology especially 
in Germany and England favored the synthesis of new drugs for disease treatment.  The 
chemist Galewsky synthesized dithranol (cignolin) in 1916., which  permitted easier to cure 
psoriasis. The first to use it were the Galewsky brother and PC Unna (Galewsky, 1916). It 
was applied as ointment or paste (0.1%) or later as a stick for short contact therapy of 
psoriasis. 
Already Hippocrates used tars in the treatment of skin disease (mostly pine tar). Tars were 
often used during the last two centuries. Little improvement in psoriasis was obtained with 
wood tars (of pine, birch, juniper, pix betulina) containing acetic acid, phenol, carbonic acid. 
They were incorporated in ointments, paste, oils and applied directly on the skin, or used for 
baths (Leigheb, 1958). Because of their acidic character tars were irritative and also stained 
brown or purple the skin and clothes. Bituminous tars such as ichthyol were also used. 
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After the introduction of coal tar obtained from distillation of coal in the manufacture of 
illuminating gas, greater improvement in psoriasis treatment was observed. This substance 
had an antiproliferative and antimflammatory action but also had an unpleasant odor and  
irritating potential. It was also phototoxic under UVA and visible rays.  
In 1925 Goeckerman (1884-1954) used coal tar in conjunction with ultraviolet light 
irradiation (Goeckerman, 1925). Because of possible carcinogenic action this method is today 
only used in the treatment of psoriasis palmoplantaris. Ingram developed a treatment of 
psoriasis based on coal tar and UVB irradiation. 
For centuries diet was used in the treatment of different diseases. Naturally there were also 
numerous attempts to treat psoriasis with diets like low fat( Grütz and Bürger), high fat, 
vegetarian (Brocq, Buckley), low or high contains of kalium (Weirich, 1960). Probably some 
effect, if it was, can be linked to a diminished intake of calories that can lower the epidermal 
proliferation as the cells for this need energy.  
The benefical effect of sun on skin diseases was known among the old civilizations, and 
heliomarinotherapy is used also in our time. Artificial ultraviolet radiation was introduced 
in medicine by Finsen at the beginning of XX century. Alderson, in the twenties, reported an 
improvement with UVR in psoriasis (Alderson, 1923). In the last decennia lamps were 
developed with wavebands between 300 and 320 nm, with narrow spectrum around 311 nm 
and PUVA therapy. In 1973 Tronnier and Schule first found a good improvement of 
psoriasis after the topical use of psoralens and UVA (Tronnier / Schule, 1973). The next year 
JA Parish at Harvard used oral 8-methoxy- psoralens and UVA irradiation, and soon later 
H. Hönigsmannn (Parrish et al., 1974; Wolff et al., 1975) Few years later, 5- methoxypsoralen 
in photochemotherapy was introduced in Vienna (1979). This treatment was highly effective 
and gave long lasting remissions.        
At the middle of the 20th century corticosteroids were introduced into medicine. The first 
treatment of psoriasis with topical corticosteroids made M.B. Sulzberger and V.Witten in 
1952., but the local application of cortisone and hydrocortisone was without effects on 
psoriasis (Sulzberger, 1952). 
Changing the steroid molecule with fluoridation permitted to obtain more potent steroids 
like fluocinolone acetonide, betamethasone valerate and clobetasol propionate. These drugs 
were effective in clearing most cases of psoriasis. Their efficacy can be enhanced with 
occlusive dressing or using combination with salicylic acid, tars and other. The drawbacks 
of this therapy are atrophy of the skin, telangiectasias, suppression of the hypothalamus-
pituitary-adrenal axis and tachyphylaxis.  
Among other drugs employed in the treatment of psoriasis are the cytostatics and 
antimetabolits. Particular mention deserve folate inhibitors like aminopterin and 
methotrexate, introduced in the 1950s, which in disabling cases of psoriasis and psoriatic 
arthritis can give a satisfactory response (Gubner, 1951; Edmundson & Guy, 1958). In recent 
years the internal use of Cyclosporine, an immunosuppressive drug, inhibiting T cell 
activation, showed favorable results in the treatment of the disease, but a problem 
represents its nephrotoxicity (Mueller & Herrmann, 1979).  
In the ‘70s the Retinoids, analogs of Vitamin A, were introduced in treatment of psoriasis, 
especially of erythrodermic and pustular form. The introduction of systemic retinoids 
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represented a great step forward for the patients. First was synthesized isotretinoin and 
used for psoriasis in 1972, later were introduced etretinate and acitretin that showed a better 
efficacy and lower toxicity. (Orfanos & Runne, 1976; Kingston et al., 1987). They act through 
the nuclear receptors  RAR and RXR  and on the expression of genes important for the 
proliferation and differentiation of keratinocytes. Retinoids can be used in combination with 
PUVA. It is important to avoid their use during pregnancy being teratogenic (Lammer et al., 
1985).  
Last decades analogs of vitamin D3 (calcipotriol, tocalcitol) showed to slowing the 
epidermopoiesis and stimulate the differentiation of keratinocytes in cultures and were 
introduced in the topical treatment of psoriasis (Smith et al., 1986). 
3.3 The future: The 21th century  
Decades of research evidenced he importance of the immune mechanisms in the insurgence 
of psoriasis. The introduction of  biological agents in he therapy of psoriasis and further 
elucidation  in the pathogenesis of the disease (Tutrone et al., 2004) permitted us to believe 
to bolster in the future use of drugs that act on specific receptors (IL-2), cytokines, 
chemokines or on some other molecules of the lymphocytes (Mrowietz, 2003). Monoclonal 
antibody humanized or recombinant and fusion proteins will find employment in the 
treatment of psoriasis as they can act on molecules on the surface of lymphocytes such CD4, 
CD2, or on molecules present on the surface of antigen presenting cells. Other may block 
some of the proimflammatory cytokines like tumor necrosis factor α or perhaps interleukins 
that deviate the TH1 to TH2 immune response. Monitoring for infections, autoimmune 
reactions are necessary.  
Also, the discovery done by O’Daly opens a new door for understanding and treatment of 
psoriasis. While injecting volunteers with vaccine for prevention of leishmaniasis, clinical 
remission of psoriasis was observed. The results confirmed in a controlled study 
demonstrated favorable benefit/risk profile and merits further development for the 
treatment of psoriasis (O’Daly et  al.,2008). There are factors in Leishmania species which 
induce remission of psoriasis by stimulating lymphocytes (O’Daly et al; 2010).  Furthermore, 
Antigens from Leishmania amastigotes inducing clinical remission of psoriatic arthritis 
(O’Daly et al.,2011). 
The new local, systemic, photochemotherapy and psychological treatments can be a 
substantial aid in the management of the disease, and will permit to improve the quality of 
life in psoriatic patients. Psoriasis vulgaris and other forms burden are not only related to 
alteration of the skin, but frequently can involve also to the joints, cardiovascular problems, 
and a metabolic syndrome. This historical review of psoriasis and its treatment from the 
Ancient times until today, alike the study of the skin and its diseases, illustrate efficiently 
the complexity of its etiology, the dilemmas of language barriers, chaos of the confounding 
nomenclature that endurated in this fields, and this is well illustrated by the innumerable 
books and articles written in the last centuries about this enigmatic disease. 
Psoriasis as a common disease has a significant socio-economic impact on the individual 
and on the society.Today dermatology and so fairly psoriasis need the support of other 
scientific disciplines like molecular medicine, genetics, immunology, and pharmacogenetics.   
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